<DOC>
	<DOCNO>NCT01159223</DOCNO>
	<brief_summary>This study compare efficacy safety ATV/r either 200/100 mg 300/100mg give daily Thai patient combination 2NRTIs .</brief_summary>
	<brief_title>Low Dose Atazanavir/r Versus Standard Dose Atazanavir/r ( LASA )</brief_title>
	<detailed_description>To demonstrate non-inferiority treatment atazanavir/ritonavir ( ATV/r ) 200/100 mg daily ( OD ) compare control group ( ATV/r 300/100 mg OD ) regard proportion virologic responder ( plasma HIV RNA &lt; 200 copies/mL ) 48 week ARV-experienced HIV-1 infected subject .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>1 . HIV infect adult age equal 18 year 2 . Received ritonavir boost PIbased HAART &gt; 3 month prior screen visit 3 . History HIV RNA &lt; 50 copies/ml within 12 month prior screen visit 4 . HIVRNA &lt; 50 copies/ml screen visit 5 . Signed write informed consent 1 . Active AIDSdefining disease active opportunistic infection 2 . History virological failure ( plasma HIVRNA ≥1,000 copies/ml ) use ritonavir boost PIbased HAART 3 . Pregnancy lactation screen visit 4 . Relevant history current condition illness might interfere drug absorption , distribution , metabolism excretion e.g . chronic diarrhea , malabsorption 5 . Use concomitant medication may interfere pharmacokinetics study drug e.g . rifampicin , proton pump inhibitor 6 . History sensitivity/idiosyncrasy drug chemically related compound may employ study 7 . ALT ≥200 IU/L screen visit 8 . Creatinine clearance &lt; 60 c.c . per min CockroftGault formula screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>atazanavir / ritonavir</keyword>
	<keyword>low dose</keyword>
	<keyword>noninferiority</keyword>
	<keyword>safety efficacy</keyword>
	<keyword>efficacy safety lower dose atazanavir/ritonavir suppress HIV-infected adult</keyword>
</DOC>